Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.

Eli Lilly (LLY) now carries a market capitalization nearly nine times that of Novo Nordisk (NVO), and the gap traces to dominance in the GLP-1 weight loss market.

By early 2025, LLY held 63% of the U.S. GLP-1 market versus 36% for NVO. Three factors drove the split: manufacturing infrastructure, tirzepatide's efficacy edge, and LLY's oral drug Foundayo. Tirzepatide delivers roughly 20% weight loss, compared with 14% for NVO's competing therapy.

NVO has also taken clinical hits. Data on CagriSema came in mixed, and a heart drug trial failed. Interpretation: those setbacks narrow the near-term catalyst list that could close the valuation gap, while LLY's share lead and efficacy advantage keep the market pricing it as the category leader.

The 63%/36% split and the 20% versus 14% efficacy gap give the market a concrete, quantifiable basis for the premium. That makes the spread a fundamentals-backed relationship rather than pure sentiment, though a ratio this wide also raises the bar for LLY to keep executing.